nach oben

Drugs

Erschienen in:

01.01.2001 | Adis New Drug Profile

Inhaled Budesonide/Formoterol Combination

verfasst von: Jane K. McGavin, Karen L. Goa, Blair Jarvis

Erschienen in: Drugs | Ausgabe 1/2001

Einloggen, um Zugang zu erhalten

Abstract

▴ Current evidence suggests that the addition of the long acting inhaled β₂-agonist formoterol to low or moderate doses of the inhaled corticosteroid budesonide is effective in improving lung function and reducing the incidence of asthma exacerbations.

▴ Concurrent use of budesonide with formoterol does not result in any untoward interaction that affects the pharmacodynamic or pharmacokinetic profiles of the individual drugs, or their adverse effect profiles.

▴ The administration of combined budesonide/formoterol is effective in improving morning and evening peak expiratory flow rates in adults with persistent asthma. Control of asthma symptoms is also significantly improved.

▴ In children aged 4 to 17 years, combined budesonide/formoterol is effective in increasing both morning and evening peak expiratory flow rates and significantly improving forced expiratory volume in 1 second (FEV₁).

▴ The most commonly encountered adverse effects in clinical trials with combination budesonide/formoterol therapy have been respiratory infection, pharyngitis and coughing. No adverse effects on pulse rate, blood pressure or serum potassium have been reported with combination therapy.

Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219–24PubMedCrossRef

Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481–8PubMed

Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group [published erratum appears in N Engl J Med 1998 Jan 8;338 (2): 139]. N Engl J Med 1997 Nov 13; 337: 1405–11PubMedCrossRef

National Institutes of Health. National Asthma Education and Prevention Program Expert Panel Report 2: guidelines for the diagnosis and management of asthma [online]. National Heart, Lung and Blood Institute 1997 July. Available from: URL: http://www.nhlbi.nih.gov/health/prof/lung/asthma/ [Accessed 2000 Dec 14]

The British Guidelines on Asthma Management 1995 Review and Position Statement. Thorax 1997; 52 Suppl. 1: 1–21CrossRef

Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 1999; 58 Suppl. 4: 25–33CrossRef

Bartow R, Brogden RN. Formoterol: an update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998 Feb; 2: 303–22CrossRef

Hvizdos KM, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 2000; 60(5): 1–38CrossRef

Boobis A. Comparative physiochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide. Respir Med 1998; 92 Suppl. B: 2–6PubMedCrossRef

10.

Edsbacker S. Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 1999; 58 Suppl. 4: 7–16CrossRef

11.

Rabe K, Jörres R, Nowak D, et al. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993; 147: 1436–41PubMed

12.

Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484–9PubMedCrossRef

13.

Szefler SJ. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol 1999; 104: S175–83CrossRef

14.

Taylor DR, Hancox RJ. Interactions between corticosteroids and β agonists. Thorax 2000; 55: 595–602PubMedCrossRef

15.

Lipworth B. Airway subsensitivity with long-acting β₂-agonists. Is there cause for concern? Drug Saf 1997; 16(5): 295–308

16.

Tan KS, Grove A, McLean A, et al. Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 1997 Jul; 156: 28–35PubMed

17.

Aziz I, Lipworth BJ. A bolus of inhaled budesonide rapidly reverses airway subsensitivity and β2-adrenoceptor down-regulation after regular inhaled formoterol. Chest 1999 Mar; 115: 623–8PubMedCrossRef

18.

Beasley R, Pearce N, Crane J, et al. β-Agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? J Allergy Clin Immunol 1999 Aug; 104 Suppl. 2: S18–30PubMedCrossRef

19.

Kips JC, O’Connor BJ, Inman MD, et al. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000 Mar; 161(3 Pt 1): 996–1001PubMed

20.

Centanni S, Carlucci P, Santus P, et al. Non-pulmonary effects induced by the addition of formoterol to budesonide therapy in patients with mild or moderate persistent asthma. Respiration 2000; 67: 60–4PubMedCrossRef

21.

Palmqvist M, Arvidsson P, Beckman O, et al. Onset of bronchodilation of budesonide/formoterol vs salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther. In press

22.

Ankerst J, Persson G, Weibull E. A high dose of budesonide/formoterol in a single inhaler was well tolerated by asthmatic patients [abstract]. World Congress on Lung Health and 10th ERS Annual Congress. Eur Respir J 2000 Aug; 16 Suppl. 31: 33S

23.

Astra USA. Pulmicort Turbuhaler (budesonide inhalation powder) prescribing information. Westborough, MA, 1998

24.

Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7: 1839–44PubMedCrossRef

25.

Granlund KM, Asking L, Lindblad T, et al. An in-vitm comparison of budesonide/formoterol and fluticasone/salmeterol in dry powder inhalers [abstract]. World Congress on Lung Health and 10th ERS Annual Congress. Eur Respir J 2000 Aug; 16 Suppl. 31: 455S

26.

Lindblad T, Granlund KM, Rollwage U, et al. Characteristics of a dry powder inhaler containing both budesonide and formoterol [abstract]. World Congress on Lung Health and 10th ERS Annual Congress. Eur Respir J 2000 Aug; 16 Suppl. 31: 455S

27.

Zetterström O, Buhl R, Mellem H, et al. Symbicort® (budesonide and formoterol in a single inhaler) improves asthma control compared with budesonide alone: a randomised controlled study. Eur Respir J. In press

28.

Tal A, Simon G, Vermeulen J, et al. The benefit of the new single inhaler product containing both budesonide and formoterol in asthmatic children [abstract]. World Congress on Lung Health and 10th ERS Annual Congress. Eur Respir J 2000 Aug; 16 Suppl. 31: 384S

29.

Vermeulen J, Simon G, Tal A, et al. Improved lung function and rapid control achieved with the new single inhaler product containing both budesonide and formoterol in asthmatic children aged 4–17 years [abstract]. World Congress on Lung Health and 10th ERS Annual Congress. Eur Respir J 2000 Aug; 16 Suppl. 31: 384S

30.

Lalloo UG, Malolepszy J, Kozma D, et al. Low-dose Symbicort® (budesonide/formoterol) is more effective than double-dose inhaled corticosteroid in mild asthma [abstract]. XVII International Congress of Allergology and Clinical Immunology; 2000 Oct 15–20; Sydney

31.

Lalloo UG, Malolepszy J, Kozma D, et al. Low-dose Symbicort® (budesonide/formoterol) controls exacerbations better than double-dose ICS in mild asthma [abstract]. XVII International Congress of Allergology and Clinical Immunology; Oct 15–20; Sydney

32.

Ringdal N, Chuchalin AG, Chovan L, et al. A comparison of Advair™/Seretide™ (salmeterol 50μg/fluticasone propionate 250μg bid) with formoterol 12μg + budesonide 800μg bid in moderate-severe asthma [abstract]. Am J Respir Crit Care Med; 2000: 196

33.

Juniper EF, Svensson K, O’Byrne PM, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999 Nov; 14: 1038–43PubMedCrossRef

34.

Tal A, Vermeulen JH, Vit P, et al. Symbicort® Turbuhaler® provides improved effect in asthmatic children treated with inhaled corticosteroids [poster]. XVII International Congress of Allergology and Clinical Immunology; Oct 15–20; Sydney

Titel: Inhaled Budesonide/Formoterol Combination
verfasst von: Jane K. McGavin
Karen L. Goa
Blair Jarvis
Publikationsdatum: 01.01.2001
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 1/2001
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200161010-00007

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Inhaled Budesonide/Formoterol Combination

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2001

Treatments for Androgenetic Alopecia and Alopecia Areata

Olanzapine

The Role of Fluoroquinolones in Tuberculosis Today

Emergence of Methicillin-Resistant Staphylococcus aureus with Intermediate Glycopeptide Resistance

The Emerging Roles of Non-Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Therapy

Budesonide/Formoterol Combination